Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Contributed by: GlobeNewswire

Tags

EHC

More Like This

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

JOURNAVX bottle and tablet (Photo: Business Wire)

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

PR Newswire associated0

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome